Sancilio Pharmaceuticals Company, Inc.
Riviera Beach
Florida
United States
About Sancilio Pharmaceuticals Company, Inc.
Sancilio Pharmaceuticals Company, Inc. (SPCI) is a fully integrated, specialty pharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products, including those based on our proprietary Advanced Lipid Technologies® (ALT®) platform. SPCI is pursuing treatments for sickle cell disease, short bowel syndrome and severe hypertriglyceridemia. We utilize our cGMP compliant facility to develop and manufacture our products. Our ALT® platform is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs). Lipids are hydrophobic or amphipathic molecules, including fatty acids, steroids (including hormones) and fat-soluble vitamins (such as vitamins A, D, E and K). Our business model is to apply our ALT® platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases resulting from imbalances of lipids in the body. In addition to our primary focus of developing our proprietary products using the ALT® platform, we make use of, and license rights to, our proprietary ALT® platform and other technologies to third parties, providing both development and subsequent soft gelatin encapsulation services. More information is available at Sancilio.com.YEAR FOUNDED:
2004
LEADERSHIP:
CEO: Fred Sancilio
7 articles about Sancilio Pharmaceuticals Company, Inc.
-
Biotech Bankruptcies Skyrocket
12/22/2023
From Statera Biopharma and Sorrento Therapeutics to Aceragen and Infinity Pharmaceuticals, 2023 has seen a record high 28 bankruptcies in the biotech space so far. Here’s why. -
Sancilio Pharmaceuticals Company to Present New Research on Altemia™ to Treat Sickle Cell Disease at the ASPHO Conference
4/30/2018
Results of the study improve our understanding of how Altemia may address several key manifestations of Sickle Cell Disease (SCD) that help inform our selection of endpoints for a pivotal study in children afflicted with this devastating disease.
-
Sancilio Pharmaceuticals Company Announces Altemia™ Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Pediatric Patients with Sickle Cell Disease (SCD)
4/3/2018
This follows the Orphan Drug Designation for Altemia granted by the U.S. Food and Drug Administration (FDA) in 2015
-
Sancilio Pharma Release: Altemia Achieves Successful Clinical Results in Pediatric Patients With Sickle Cell Disease
11/1/2017
Statistically significant improvements in markers of coagulation (D-Dimer), inflammation (C-Reactive Protein) and adhesion (E-selectin), key elements associated with the clinical manifestations of SCD, were seen after 8 weeks of treatment.
-
Sancilio Pharmaceuticals Company, Inc. Announces The Successful Completion Of A Randomized, Double Blind, And Placebo Controlled Phase Of A Clinical Trial In Pediatric Patients With Sickle Cell Disease Using Altemia
10/3/2017
-
Sancilio Pharmaceuticals Company, Inc. Receives Rare Pediatric Disease Designation From The FDA For Altemia A Treatment Of Sickle Cell Disease (SCD) In Children
9/20/2017
-
Sancilio Pharmaceuticals Company, Inc. Announces Completion Of Enrollment In The SCOT Trial In Pediatric Patients With Sickle Cell Disease Using Altemia Capsules
7/27/2017